血友病以外的罕见凝血因子缺乏症的治疗
The deficiency of fibrinogen, prothrombin, factor V (FV), FVII, FVIII, FIX, FX, FXI, and FXIII, called rare coagulation disorders (RCDs), may result in coagulopathies leading to spontaneous or posttrauma and postsurgery hemorrhages.…
要点
- FVII和FXIII缺乏有特异性重组蛋白,而FII或FV缺乏无特异性产品。
- RNA干扰、抗组织因子途径抑制物和基因治疗等新方法可能在未来用于罕见凝血障碍。
核心结论
- 罕见凝血障碍临床表现异质性大且患者数量少,导致适当治疗的发展延迟;未来非替代治疗和基因治疗可能发挥重要作用。
研究设计与样本
- 综述,未报告检索范围。
主要发现
- 所有罕见凝血障碍最典型的症状是黏膜出血和侵入性操作时出血,而中枢神经系统出血和关节积血等危及生命的症状主要见于无纤维蛋白原血症、FX和FXIII缺乏症。
- FVII和FXIII缺乏患者有特异性重组蛋白可用,而FII或FV缺乏患者至今仅能选择凝血酶原复合物浓缩物或新鲜冰冻血浆。
- 血友病的新型止血方法(如RNA干扰、抗组织因子途径抑制物和基因治疗)也可能在未来用于罕见凝血障碍患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The deficiency of fibrinogen, prothrombin, factor V (FV), FVII, FVIII, FIX, FX, FXI, and FXIII, called rare coagulation disorders (RCDs), may result in coagulopathies leading to spontaneous or posttrauma and postsurgery hemorrhages. RCDs are characterized by a wide variety of symptoms, from mild to severe, which can vary significantly from 1 disease to another and from 1 patient to another. The most typical symptoms of all RCDs are mucosal bleedings and bleeding at the time of invasive procedures, whereas other life-threatening symptoms such as central nervous system bleeding and hemarthroses are mostly present only in some deficiencies (afibrinogenemia, FX, and FXIII). At variance with hemophilia A and B and von Willebrand disease, RCDs are much less prevalent, ranging from 1 case in 500 000 to 1 in 2 million in the general population. Their clinical heterogeneity associated with the low number of patients has led to a delay in the development of appropriate therapies. Indeed, a similar heterogeneity can also be found in the treatment products available, ranging from the specific recombinant proteins to treat FVII- and FXIII-deficient patients to the complete absence of specific products to treat patients with FII or FV deficiencies, for whom prothrombin complex concentrates or fresh frozen plasma are, to date, the only option. The recent development of novel hemostatic approaches for hemophilia, such as the use of nonsubstitutive therapy as RNA interference, anti-tissue factor pathway inhibitor, and the gene therapy aimed at improving the patient's quality of life may also have an important role in the treatment of patients with RCDs in the future.
引用
- Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood. 2018. PMID: 30559262. doi:10.1182/blood-2018-06-820738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。